Designating People with Intellectual and Developmental Disabilities as a Medically Underserved Population: Putting Health in Policy
The federal government defines MUP in terms of groups that occupies the same neighborhood, census tract or geographic area. This puts people with intellectual and developmental disabilities (I/DD) in a Catch-22. Though as a population, people with I/DD experience a lack of primary care providers, significant rates of poverty, increased infant mortality, and an aging population, the I/DD population can never meet the MUP designation standard because they do not live in segregated communities. This means people with I/DD, now woven into the fabric of our communities, cannot benefit from what other medically underserved populations receive to remedy their health disparities and lack of access to health care.
This paper identifies a critical opportunity for law change to improve the public health of people with I/DD, for people with some familiarity with law. It presents a little known exception under the law, and possible law changes to include people with I/DD as an MUP and improve their health as a population.
Learning Areas:Advocacy for health and health education
Public health or related public policy
Explain the opportunity for changes to law and regulations to promote the health of the population of people with I/DD by becoming a medically undersserved population
Keyword(s): Health Law, Health Disparities/Inequities
Qualified on the content I am responsible for because: I am an attorney, and professor of Occupational Therapy,(previously public health). I I was a Robert Wood Johnson Health Policy Fellow. I was appointed by HHS Secretary Sebelius to serve on HRSAâs Negotiated Rulemaking Committee on Medically Underserved Populations and Health Profession Shortage Areas. I have lectured nationally and published articles and book chapters on disability health disparities and disability policy. I advised Harkin on disability issues.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.